Takeda Pharmaceutical (NYSE:TAK) Sees Unusually-High Trading Volume – Still a Buy?

Takeda Pharmaceutical Company Limited (NYSE:TAK) shares saw an uptick in trading volume on Wednesday . 853,714 shares were traded during mid-day trading, a decline of 47% from the previous session’s volume of 1,609,208 shares.The stock last traded at $13.23 and had previously closed at $13.35.

Takeda Pharmaceutical Trading Down 2.0 %

The company’s 50 day simple moving average is $13.48 and its 200 day simple moving average is $13.88. The firm has a market cap of $41.27 billion, a price-to-earnings ratio of 22.36, a P/E/G ratio of 0.25 and a beta of 0.51. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77.

Hedge Funds Weigh In On Takeda Pharmaceutical

Institutional investors have recently modified their holdings of the business. Millennium Management LLC grew its stake in shares of Takeda Pharmaceutical by 87.1% during the second quarter. Millennium Management LLC now owns 4,346,151 shares of the company’s stock worth $56,239,000 after purchasing an additional 2,023,707 shares in the last quarter. FMR LLC grew its stake in shares of Takeda Pharmaceutical by 10.9% during the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock worth $41,365,000 after purchasing an additional 286,052 shares in the last quarter. Stifel Financial Corp grew its stake in shares of Takeda Pharmaceutical by 103.9% during the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock worth $6,266,000 after purchasing an additional 224,594 shares in the last quarter. Summit Global Investments grew its stake in shares of Takeda Pharmaceutical by 86.0% during the third quarter. Summit Global Investments now owns 415,558 shares of the company’s stock worth $5,909,000 after purchasing an additional 192,143 shares in the last quarter. Finally, Van ECK Associates Corp grew its stake in shares of Takeda Pharmaceutical by 6.6% during the third quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock worth $30,149,000 after purchasing an additional 134,407 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.